Shield Therapeutics plc (AIM:STX)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 106.84M |
| Revenue (ttm) | 30.29M |
| Net Income (ttm) | -15.50M |
| Shares Out | 1.07B |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 680,733 |
| Average Volume | 1,457,894 |
| Open | 10.00 |
| Previous Close | 10.00 |
| Day's Range | 9.50 - 10.50 |
| 52-Week Range | 2.10 - 12.50 |
| Beta | 1.96 |
| RSI | 46.08 |
| Earnings Date | Apr 24, 2026 |
About Shield Therapeutics
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom. [Read more]
Financial Performance
In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.
Financial numbers in USD Financial StatementsNews
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX
NEW YORK, May 17, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics PLC (LSE: STXS; OT...